Page 6,942«..1020..6,9416,9426,9436,944..6,9506,960..»

Walk MS event raises money for multiple sclerosis research

Posted: Published on March 31st, 2012

Published: Friday, March 30, 2012 at 2:49 p.m. Last Modified: Friday, March 30, 2012 at 2:49 p.m. Mansfield does not remember a time when her mother was not confined to a wheelchair, visible evidence of her mother's battle with the disease that eventually took her life. My mom was diagnosed with multiple sclerosis when I was just five years old, said Mansfield. I had to watch her struggle for 10 years with the effects of MS until she passed away when I was 15. In memory of her mother, Mansfield will be participating in Tuscaloosa's Walk MS event Saturday sponsored by the Alabama-Mississippi chapter of the National Multiple Sclerosis Society. Amanda Burton, event manager, said that Walk MS not only brings together people in the community who are affected by MS, but it also supports research and helps people with the disease move forward with their lives. Check-in for the event begins at 8:30 am at Snow Hinton Park, and the walk begins at 9:30 am. The event will offer one-, two-, and three-mile route options. The Walk MS event has existed in Alabama for 25 years, said Burton. This will be the third year that Tuscaloosa has hosted an … Continue reading →

Posted in MS Treatment | Comments Off on Walk MS event raises money for multiple sclerosis research

Panel seeks funding cut over stem cell research, health insurance

Posted: Published on March 31st, 2012

Left, Michigan State University's Beaumont Tower; Right, the Michigan Union on the campus of the University of Michigan. / Courtesy MSU & JARRAD HENDERSON/Detroit Free Press (Detroit Free Press)- Republican members of the Michigan House higher education committee flexed their muscles Friday, passing a budget recommendation that would strip state aid from Michigan's two most prominent universities over disagreements on stem cell research and mandatory student health insurance. The Republicans have been feuding with both the University of Michigan and Michigan State University in the past year over the two social issues and has threatened to pull state aid over it. But neither MSU or U-M blinked at the move. "We believe there are elements in this proposal that are intended to be punitive in nature and that it would force us to raise tuition more than anticipated," said Heather Swain, MSU's vice president for university relations. This budget recommendation, which would still have to be passed by the full committee, the full House, the Senate and eventually signed by the governor, would make good on the previous threats. At risk is U-M's and MSU's share of nearly $40 million in performance funding, which, under the House plan, would be … Continue reading →

Posted in Stem Cell Research | Comments Off on Panel seeks funding cut over stem cell research, health insurance

Stem cell, health insurance stances may cost U-M, MSU state aid

Posted: Published on March 31st, 2012

Republican members of the Michigan House higher education committee flexed their muscles Friday, passing a budget recommendation that would strip state aid from Michigans two most prominent universities over disagreements on stem cell research and mandatory student health insurance. The Republicans have been feuding with both the University of Michigan and Michigan State University in the past year over the two social issues and has threatened to pull state aid over it. But neither MSU or U-M blinked at the move. We believe there are elements in this proposal that are intended to be punitive in nature and that it would force us to raise tuition more than anticipated, said Heather Swain, MSUs vice president for university relations. This budget recommendation, which would still have to be passed by the full committee, the full House, the Senate and eventually signed by the governor, would make good on the previous threats. At risk is U-Ms and MSUs share of nearly $40 million in performance funding, which, under the House plan, would be doled out to those universities meeting a number of criteria. We are, of course, disappointed that the House higher-education budget proposal restricts funding for U-M over the way the … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cell, health insurance stances may cost U-M, MSU state aid

Levi Garraway on cancer cell genetic profile catalogs | Dana-Farber Cancer Institute – Video

Posted: Published on March 31st, 2012

30-03-2012 11:44 Personalized medicine is becoming an increasingly important aspect of cancer treatment. Levi Garraway, MD, PhD, of Dana-Farber Cancer Institute and the Broad Institute, describes a new database of nearly 1000 cancer cell lines, across numerous tumor types, that will be used to help predict the effectiveness of cancer drugs based on a tumor's genetic profile. See the original post here: Levi Garraway on cancer cell genetic profile catalogs | Dana-Farber Cancer Institute - Video … Continue reading →

Comments Off on Levi Garraway on cancer cell genetic profile catalogs | Dana-Farber Cancer Institute – Video

Using Antiplatelet Therapy After Coronary Interventions – Study

Posted: Published on March 31st, 2012

Editor's Choice Academic Journal Main Category: Cardiovascular / Cardiology Also Included In: Heart Disease;Genetics Article Date: 30 Mar 2012 - 8:00 PDT email to a friend printer friendly opinions Current Article Ratings: Following PCI, the standard care for patients commonly consists of aspirin and clopidogrel to reduce the risk of blood clot formation, however, this dual antiplatelet therapy results in many patients becoming vulnerable to major adverse cardiovascular events. This persistent vulnerability is linked to elevated on-treatment platelet reactivity, which can lead to a sudden blockage in the stents that can cause heart attacks or death. The characteristics of elevated on-treatment platelet reactivity are inadequate inhibition of the platelet PsY12 receptor following clopidogrel treatment. According to scientists, numerous clinical variables have been implicated, however, the strongest predictor is the loss-of-function CYP2C19*2 allele (rs4244285), which is a common genetic variant that occurs in almost 30% of western Europeans and in about 50% of Asians. Two unique P2Y12 inhibitors are prasugrel and ticagrelor, which compared with clopidogrel provide a more potent platelet inhibition. Although both drugs reduce major adverse cardiovascular events following acute coronary syndrome, they are also linked to higher complications in terms of bleeding. The researchers point out that retrospective … Continue reading →

Comments Off on Using Antiplatelet Therapy After Coronary Interventions – Study

Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult …

Posted: Published on March 31st, 2012

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR - News) announced the presentation of results from a post-hoc subgroup analysis of the company's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID (fidaxomicin) tablets compared to oral vancomycin. The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The analysis included 153 patients with active cancer who were treated in the two DIFICID Phase 3 studies and who received 8 days or more of treatment with DIFICID or oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence. Specifically, DIFICID provided superior response compared to vancomycin across all clinical endpoints studied: clinical response (97.3% vs. 87.5%, 95% CI 1.07-23.98; p=0.041), sustained response (83.6% vs. … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult …

Penn Medicine Cardiovascular Researcher Honored by American Medical Association for Promising Work in Congenital Heart …

Posted: Published on March 31st, 2012

PHILADELPHIA Rajan Jain, MD, cardiovascular fellow, Hospital of the University of Pennsylvania, has been honored with an American Medical Association (AMA) 2012 Seed Grant Research Program award for his promising research into congenital heart disease. "I'm very excited to have received this grant," said Dr. Jain. "Congenital heart disease is among the most prevalent congenital abnormalities, but surprisingly, we know very little about how the various abnormalities occur. We hope to continue to understand the fundamentals of cardiac development and to eventually provide novel avenues of diagnostics and therapeutics for patients with congenital heart disease." Dr. Jain, working under the guidance Jonathan A. Epstein, MD, scientific director of the Penn Cardiovascular Institute and chair, Department of Cell and Developmental Biology, William Wikoff Smith Professor of Cardiovascular Research, Perelman School of Medicine, is interested specifically in how the aortic valve and aorta are formed, and how this process goes wrong in patients with congenital heart disease. Dr. Jain is one of 43 junior investigators nationwide awarded a grant by this initiative for basic science or clinical research projects in the areas of cardiovascular/pulmonary diseases, HIV/AIDS, neoplastic diseases and pancreatic cancer. The AMA's grant research program supports grant-writing and research skills in … Continue reading →

Posted in Cell Medicine | Comments Off on Penn Medicine Cardiovascular Researcher Honored by American Medical Association for Promising Work in Congenital Heart …

PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012

Posted: Published on March 31st, 2012

WALTHAM, Mass.--(BUSINESS WIRE)-- At the American Association for Cancer Research 2012 Annual Meeting (Booth #2306), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will be showcasing numerous solutions, posters and knowledge-sharing events in support of cancer-focused personalized medicine research. "PerkinElmer remains committed to the fight against cancer through enabling personalized medicine solutions that allow researchers to find, understand, and act upon the causes and processes of the disease, said Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer. We are passionate about helping academic, biopharma and clinical researchers to achieve new insights for discovering advanced therapeutics and diagnostics to reduce the threat of cancer. Our solutions in Next Generation Sequencing, advanced cellular, in vitro and in vivo imaging, automation instrumentation, and reagent technologies, provide researchers the critical tools they need to combat this deadly disease." On the evening of Tuesday, April 3, PerkinElmer will be hosting an event, entitled "The Revolutionizing Medicine Rock 'n' Roll Reception," featuring distinguished speakers who are committed to the fight against cancer, discussing how personalized medicine is changing research and treatment of the disease. The event will also feature performances by Molecular Groove, … Continue reading →

Posted in Cell Medicine | Comments Off on PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012

UPDATE 1-Roche set to file armed antibody breast cancer drug

Posted: Published on March 31st, 2012

* T-DM1 superior to Tykerb plus Xeloda in Phase III study * Filing planned for Europe (Chicago Options: ^REURUSD - news) and U.S. this year * T-DM1 delivers toxic payload with fewer side effects (Adds details on drug, reduced side effects) ZURICH, March 30 (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a mix of GlaxoSmithKline (Other OTC: GLAXF.PK - news) drug Tykerb and Roche's Xeloda. The positive results from the first Phase III trial of the medicine - dubbed T-DM1 - clears the way for it to be submitted to European and U.S. authorities for approval this year, boosting prospects for a key asset in the Swiss firm's pipeline. Roche has been developing T-DM1 with ImmunoGen (NasdaqGM: IMGN - news) as a successor to its blockbuster Herceptin, which is expected to generate sales of around $6 billion this year. A key advantage of T-DM1 over Herceptin is the fact that it causes fewer adverse side effects like hair loss and low white blood cell counts. It combines trastuzumab, an antibody and the active ingredient in Herceptin, with the agent … Continue reading →

Posted in Drug Side Effects | Comments Off on UPDATE 1-Roche set to file armed antibody breast cancer drug

Side-effects of drug price control

Posted: Published on March 31st, 2012

The Department of Pharmaceuticals' decision to stick to cost-based pricing will put drugs out of reach of the poor. Market pricing will improve access to medicines by spurring competition in the industry. March 30, 2012: The figures just don't add up for Nathu Ram, a daily-wage earner, who supports a family of five. Eking out a meagre existence on Rs 200 a day, he finds himself in an inescapable predicament: either to feed the family or foot the medical bills of his wife, diagnosed with breast cancer recently. He does try to balance it out, but even concessional treatment and medicines remain out of bounds. Nathu Ram is not an isolated case. Millions of people in India don't have access to essential medicines. Just making drugs cheaper doesn't help their case. Nor does rhetoric! It's time we understood why the well-drafted National Pharmaceutical Pricing Policy (NPPP) 2011 might not meet its avowed objectives. Directed by the Supreme Court, the Department of Pharmaceuticals (DoP) set the tone for the NPPP 2011 with a focus on improving access to essential medicines and encouraging industry competition through a market-based pricing policy. But since then, there has been a series of flip-flops on its … Continue reading →

Posted in Drug Side Effects | Comments Off on Side-effects of drug price control

Page 6,942«..1020..6,9416,9426,9436,944..6,9506,960..»